Skip to main content

Milestone 7.B

Initiate research programs for translational bioinformatics and network pharmacology to support rational drug repositioning and combination therapy from discovery through clinical development.


Success Criteria

Identification of at least 6 existing drugs suitable for repurposing and/or combination therapy for AD and ADRD prevention or treatment.  The drugs selected for repurposing or combination therapy will be prioritized based on:

  • evidence that they modulate disease relevant pathways/networks gained from computational and empirical approaches.

  • preclinical proof-of-efficacy in a relevant model system.

  • availability of biomarkers to monitor target engagement in humans.

  • sufficient evidence of safety for the intended target population.


Research Implementation Area
Drug Repurposing and Combination Therapy Development
Timeline
2016–2022
Status
Achieved

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations